India Launches Indigenous Tetanus and Adult Diphtheria Vaccine under Universal Immunization Programme
Union Health Minister J.P. Nadda launched the indigenously manufactured Tetanus and adult Diphtheria (Td) vaccine at the Central Research Institute (CRI) in Kasauli. This marks a significant milestone as CRI becomes the first government institute to manufacture vaccines under Good Manufacturing Practices (GMP) standards. The vaccine has been introduced for supply under the Universal Immunization Programme (UIP), with an initial supply of 55 lakh doses. This move strengthens India's public health infrastructure and reinforces its status as the 'pharmacy of the world,' following the successful development of indigenous COVID-19 vaccines.
Key Points
- The Td vaccine is indigenously manufactured by the Central Research Institute (CRI), Kasauli, strengthening national health security.
- CRI is the first government institute to achieve Good Manufacturing Practices (GMP) standards for vaccine production.
- The vaccine will be integrated into the Universal Immunization Programme (UIP), which is the world's largest immunization program.
- The initiative reflects the modernization of public sector vaccine manufacturing units in India.
Exam Facts
- Central Research Institute (CRI) is located in Kasauli, Himachal Pradesh.
- The Universal Immunization Programme (UIP) currently protects against 12 vaccine-preventable diseases.
- Initial supply target for the Td vaccine is 55 lakh doses through UIP.
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.